It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Enhancing the properties of advanced drug candidates is aided by the direct incorporation of specific chemical groups, avoiding the need to construct the entire compound from the ground up. Nevertheless, their chemical intricacy often poses challenges in predicting reactivity for C-H activation reactions and planning their synthesis. We adopted a reaction screening approach that combines high-throughput experimentation (HTE) at a nanomolar scale with computational graph neural networks (GNNs). This approach aims to identify suitable substrates for late-stage C-H alkylation using Minisci-type chemistry. GNNs were trained using experimentally generated reactions derived from in-house HTE and literature data. These trained models were then used to predict, in a forward-looking manner, the coupling of 3180 advanced heterocyclic building blocks with a diverse set of sp3-rich carboxylic acids. This predictive approach aimed to explore the substrate landscape for Minisci-type alkylations. Promising candidates were chosen, their production was scaled up, and they were subsequently isolated and characterized. This process led to the creation of 30 novel, functionally modified molecules that hold potential for further refinement. These results positively advocate the application of HTE-based machine learning to virtual reaction screening.
Late-stage functionalization of drug molecules can tune their properties without the need for entirely new syntheses, however, predicting reactivity and planning synthesis for late-stage C-H activation remains challenging. Here, the authors develop a reaction screening approach combining high-throughput experimentation with computational graph neural networks to identify suitable substrates that can be used for late-stage C-H alkylation via Minisci-type chemistry.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details








1 F. Hoffmann-La Roche Ltd., Roche Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland (GRID:grid.417570.0) (ISNI:0000 0004 0374 1269); Ludwig-Maximilians-Universität München, Department of Pharmacy, Munich, Germany (GRID:grid.5252.0) (ISNI:0000 0004 1936 973X)
2 ETH Zurich, Department of Chemistry and Applied Biosciences, Zurich, Switzerland (GRID:grid.5801.c) (ISNI:0000 0001 2156 2780)
3 F. Hoffmann-La Roche Ltd., Roche Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland (GRID:grid.417570.0) (ISNI:0000 0004 0374 1269)
4 Ludwig-Maximilians-Universität München, Department of Pharmacy, Munich, Germany (GRID:grid.5252.0) (ISNI:0000 0004 1936 973X)